{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:50:28Z","timestamp":1792104628665,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020196","name":"Shandong Provincial Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["SDZZ-ZR-202501220"],"award-info":[{"award-number":["SDZZ-ZR-202501220"]}],"id":[{"id":"10.13039\/501100020196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["79th Batch, 2026M793923"],"award-info":[{"award-number":["79th Batch, 2026M793923"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477085"],"award-info":[{"award-number":["22477085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119416","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:56:27Z","timestamp":1791906987000},"page":"119416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Discovery of novel CDK9 inhibitors containing 1H-pyrrolo[2,3-b]pyridine moiety for treatment of colorectal cancer"],"prefix":"10.1016","volume":"321","author":[{"given":"Ye","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-1944","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119416_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000543921","article-title":"Colorectal cancer: epidemiology, risk factors, and public health strategies","volume":"106","author":"Matsuda","year":"2025","journal-title":"Digestion"},{"key":"10.1016\/j.ejmech.2026.119416_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119416_bib3","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.3390\/curroncol28060447","article-title":"Pathological features and prognostication in colorectal cancer","volume":"28","author":"Chen","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2026.119416_bib4","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","article-title":"Targeting cyclin-dependent kinase 9 in cancer therapy","volume":"43","author":"Shen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119416_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543776.2023.2208747","article-title":"A patent review of selective CDK9 inhibitors in treating cancer","volume":"33","author":"Wu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119416_bib6","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update","volume":"63","author":"Wu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119416_bib7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/biomedicines11030928","article-title":"Evaluation of CDK9 inhibition by dinaciclib in combination with apoptosis modulating izTRAIL for the treatment of colorectal cancer","volume":"11","author":"Shen","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119416_bib8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/1878-0261.12559","article-title":"Targeting CDK9 for treatment of colorectal cancer","volume":"13","author":"Rahaman","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119416_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2174\/1389450120666190618123846","article-title":"PI3K\/Akt\/mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence","volume":"20","author":"Narayanankutty","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2026.119416_bib10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2174\/1874467215666220124125809","article-title":"Promising anticancer activity of multitarget cyclin dependent kinase inhibitors against human colorectal carcinoma cells, curr","volume":"15","author":"Manohar","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119416_bib11","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1016\/j.apsb.2026.05.008","article-title":"CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors","volume":"16","author":"Wei","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119416_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41389-025-00574-1","article-title":"Novel CDK2\/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)","volume":"14","author":"Mohiuddin","year":"2025","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2026.119416_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119416_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/00498254.2024.2428716","article-title":"Preclinical metabolism and disposition of [14C]GFH009, a novel selective CDK9 inhibitor","volume":"54","author":"Wang","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2026.119416_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119416_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129941","article-title":"Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development","volume":"112","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119416_bib17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/D2MD00040G","article-title":"CDK9 inhibitors in cancer research","volume":"13","author":"Huang","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119416_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/14756366.2021.1890726","article-title":"Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy","volume":"36","author":"Alsfouk","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119416_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401797","article-title":"Heterocyclic compounds as CDK9 inhibitors: structural diversity, mechanism of action, and therapeutic potential in cancer and beyond","volume":"22","author":"Bose","year":"2025","journal-title":"Chem. Biodiversity"},{"key":"10.1016\/j.ejmech.2026.119416_bib20","doi-asserted-by":"crossref","first-page":"22095","DOI":"10.1021\/acs.jmedchem.5c02127","article-title":"Beyond inhibition: recent advances of heterobifunctional molecules targeting CDK9","volume":"68","author":"Yin","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119416_bib21","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1021\/acs.jmedchem.3c02329","article-title":"Identification of a novel selective CDK9 inhibitor for the treatment of CRC: Design, synthesis, and biological activity evaluation","volume":"67","author":"Zhong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119416_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/jm301495v","article-title":"Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity","volume":"56","author":"Hole","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:40:55Z","timestamp":1792104055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":22,"alternative-id":["S0223523426008615"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119416","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel CDK9 inhibitors containing 1H-pyrrolo[2,3-b]pyridine moiety for treatment of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119416"}}